Why the study?
Does therapeutic apheresis safely and effectively lower triglycerides in patients with severe hypertriglyceridemia?
Does therapeutic apheresis safely and effectively lower triglycerides in patients with severe hypertriglyceridemia?
Answers are grounded in this paper and cite their sources.
Therapeutic apheresis is a safe and useful early intervention for severe hypertriglyceridemia and associated pancreatitis, though its use is limited by cost and availability.
Hypertriglyceridemia is associated with a number of severe diseases such as acute pancreatitis and coronary artery disease. In severe hypertriglyceridemia (SHTG, triglycerides > 1,000 mg/dL), rapid lowering of plasma triglycerides (TG) has to be achieved. Treatment regimes include nutritional intervention, the use of antihyperlipidemic drugs, and therapeutic apheresis. Apheretic treatment is indicated in medical emergencies such as hypertriglyceridemic pancreatitis. Reviewing the current literature, plasmapheresis appears to be a safe and useful therapeutic tool in patients suffering from SHTG. Apheretic treatment is able to remove the causative agent for pancreatic inflammation. Data suggests that the use of apheresis should be performed as early as possible in order to achieve best results. The use of plasmapheresis, however, is limited due to the rather high costs and the limited availability of the procedure.
No takes yet. Share an insight, caveat, or question.
Ewald et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: